PandemieGrippaleV1, Main, Curation, bibRecord, 001027

Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada

Identifieur interne : 001027 ( Main/Curation ); précédent : 001026; suivant : 001028

Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada

Auteurs : Isabelle Rouleau [Canada] ; Gaston De Serres [Canada] ; Danuta M. Skowronski [Canada] ; Jean Philippe Drolet [Canada] ; Chantal Lemired [Canada] ; Eveline Toth [Canada] ; Monique Landry [Canada]

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0143864

Descripteurs français

Pascal (Inist)
- Facteur risque, Anaphylaxie, Adjuvant immunologique, Vaccin, Québec, Toxicité, Hypersensibilité, Allergie, Grippe.
Wicri :
- topic : Vaccin, Allergie.

English descriptors

KwdEn :
- Allergy, Anaphylaxis, Hypersensitivity, Immunological adjuvant, Influenza, Quebec, Risk factor, Toxicity, Vaccine.

Abstract

Introduction: In Quebec, Canada, receipt of the 2009 AS03-adjuvanted pandemic H1N1 vaccine was associated with increased risk of anaphylaxis and other allergic-like events (ALE), especially among women of childbearing age. In response to this safety signal, a case-control study was conducted to identify potential risk factors. Methods: A total of 435 ALE (50 anaphylaxis) occurring <24 h following pandemic vaccination were compared to 849 age-gender matched controls randomly selected from the provincial Pandemic Influenza Vaccination Registry. More than 60 potential risk factors were evaluated through phone interviews and included demographic information, medical history, medication use or acute respiratory illnesses (ARI) concurrent with vaccination and other risk factors associated with general allergy. Odds ratios (ORs) with 95% confidence intervals were estimated with unconditional logistic regression. Results: Factors associated with increased risk of anaphylaxis included concurrent ARI (18% cases vs. 4% controls, ORadj 7.67, 95%CI: 3.04-13.37), food allergy (26% cases vs. 4% controls, ORadj 3.84, 95%CI: 1.51-9.74) and vaccination during the first four weeks of the campaign (66% cases vs. 50% controls, ORadj 2.16,95%CI: 1.10-4.25) whereas alcohol exposure (≥1 drink/week) was associated with reduced risk (29% cases vs. 42% controls, ORadj 0.26,95%CI: 0.13-0.57). These factors were also significantly associated with any ALE but the strength of association was weaker. Allergy to components found in the vaccine (e.g., egg, thimerosal) was infrequent and did not significantly differ between cases and controls. Conclusion: Increased anaphylaxis and other allergic-like events observed in association with AS03-adjuvanted pandemic H1N1 vaccine remain mostly unexplained despite extensive risk factor review. However, prior to mass vaccination with similar formulations this safety signal warrants further consideration and better understanding. In particular, the predominance among women of childbearing age may be a clue to underlying biological or hormonal influences on adverse immunological responses to vaccine.

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000097
to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001D22
to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000034
to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :001035

Links to Exploration step

Pascal:14-0143864

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada</title>
<author><name sortKey="Rouleau, Isabelle" sort="Rouleau, Isabelle" uniqKey="Rouleau I" first="Isabelle" last="Rouleau">Isabelle Rouleau</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre hospitalier universitaire de Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre hospitalier universitaire de Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut national de santé publique du Québec</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institut national de santé publique du Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M." last="Skowronski">Danuta M. Skowronski</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>British Columbia Centre for Disease Control</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>British Columbia Centre for Disease Control</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drolet, Jean Philippe" sort="Drolet, Jean Philippe" uniqKey="Drolet J" first="Jean Philippe" last="Drolet">Jean Philippe Drolet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre hospitalier universitaire de Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lemired, Chantal" sort="Lemired, Chantal" uniqKey="Lemired C" first="Chantal" last="Lemired">Chantal Lemired</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre hospitalier universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke</s1>
<s2>Sherbrooke, Québec</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sherbrooke, Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Toth, Eveline" sort="Toth, Eveline" uniqKey="Toth E" first="Eveline" last="Toth">Eveline Toth</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1>
<s2>Montréal, Québec</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Ministère de la santé et des services sociaux du Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1>
<s2>Montréal, Québec</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Ministère de la santé et des services sociaux du Québec</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0143864</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0143864 INIST</idno>
<idno type="RBID">Pascal:14-0143864</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000097</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001D22</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000034</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000034</idno>
<idno type="wicri:doubleKey">0264-410X:2014:Rouleau I:risk:factors:associated</idno>
<idno type="wicri:Area/Main/Merge">001035</idno>
<idno type="wicri:Area/Main/Curation">001027</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada</title>
<author><name sortKey="Rouleau, Isabelle" sort="Rouleau, Isabelle" uniqKey="Rouleau I" first="Isabelle" last="Rouleau">Isabelle Rouleau</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre hospitalier universitaire de Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Serres, Gaston" sort="De Serres, Gaston" uniqKey="De Serres G" first="Gaston" last="De Serres">Gaston De Serres</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre hospitalier universitaire de Quebec</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Institut national de santé publique du Québec</s1>
<s2>Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Institut national de santé publique du Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M." last="Skowronski">Danuta M. Skowronski</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>British Columbia Centre for Disease Control</s1>
<s2>Vancouver</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>British Columbia Centre for Disease Control</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Drolet, Jean Philippe" sort="Drolet, Jean Philippe" uniqKey="Drolet J" first="Jean Philippe" last="Drolet">Jean Philippe Drolet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Centre hospitalier universitaire de Quebec</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Centre hospitalier universitaire de Quebec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Lemired, Chantal" sort="Lemired, Chantal" uniqKey="Lemired C" first="Chantal" last="Lemired">Chantal Lemired</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Centre hospitalier universitaire de Sherbrooke, Faculté de médecine et des sciences de la santé, Université de Sherbrooke</s1>
<s2>Sherbrooke, Québec</s2>
<s3>CAN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Sherbrooke, Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Toth, Eveline" sort="Toth, Eveline" uniqKey="Toth E" first="Eveline" last="Toth">Eveline Toth</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1>
<s2>Montréal, Québec</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Ministère de la santé et des services sociaux du Québec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Landry, Monique" sort="Landry, Monique" uniqKey="Landry M" first="Monique" last="Landry">Monique Landry</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Ministère de la santé et des services sociaux du Québec</s1>
<s2>Montréal, Québec</s2>
<s3>CAN</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Ministère de la santé et des services sociaux du Québec</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Allergy</term>
<term>Anaphylaxis</term>
<term>Hypersensitivity</term>
<term>Immunological adjuvant</term>
<term>Influenza</term>
<term>Quebec</term>
<term>Risk factor</term>
<term>Toxicity</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Facteur risque</term>
<term>Anaphylaxie</term>
<term>Adjuvant immunologique</term>
<term>Vaccin</term>
<term>Québec</term>
<term>Toxicité</term>
<term>Hypersensibilité</term>
<term>Allergie</term>
<term>Grippe</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term>
<term>Allergie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Introduction: In Quebec, Canada, receipt of the 2009 AS03-adjuvanted pandemic H1N1 vaccine was associated with increased risk of anaphylaxis and other allergic-like events (ALE), especially among women of childbearing age. In response to this safety signal, a case-control study was conducted to identify potential risk factors. Methods: A total of 435 ALE (50 anaphylaxis) occurring <24 h following pandemic vaccination were compared to 849 age-gender matched controls randomly selected from the provincial Pandemic Influenza Vaccination Registry. More than 60 potential risk factors were evaluated through phone interviews and included demographic information, medical history, medication use or acute respiratory illnesses (ARI) concurrent with vaccination and other risk factors associated with general allergy. Odds ratios (ORs) with 95% confidence intervals were estimated with unconditional logistic regression. Results: Factors associated with increased risk of anaphylaxis included concurrent ARI (18% cases vs. 4% controls, ORadj 7.67, 95%CI: 3.04-13.37), food allergy (26% cases vs. 4% controls, ORadj 3.84, 95%CI: 1.51-9.74) and vaccination during the first four weeks of the campaign (66% cases vs. 50% controls, ORadj 2.16,95%CI: 1.10-4.25) whereas alcohol exposure (≥1 drink/week) was associated with reduced risk (29% cases vs. 42% controls, ORadj 0.26,95%CI: 0.13-0.57). These factors were also significantly associated with any ALE but the strength of association was weaker. Allergy to components found in the vaccine (e.g., egg, thimerosal) was infrequent and did not significantly differ between cases and controls. Conclusion: Increased anaphylaxis and other allergic-like events observed in association with AS03-adjuvanted pandemic H1N1 vaccine remain mostly unexplained despite extensive risk factor review. However, prior to mass vaccination with similar formulations this safety signal warrants further consideration and better understanding. In particular, the predominance among women of childbearing age may be a clue to underlying biological or hormonal influences on adverse immunological responses to vaccine.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001027 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 001027 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    Main
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:14-0143864
   |texte=   Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada
}}

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada

Risk factors associated with anaphylaxis and other allergic-like events following receipt of 2009 monovalent AS03-adjuvanted pandemic influenza vaccine in Quebec, Canada

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri